Company profile: Seno Medical
1.1 - Company Overview
Company description
- Provider of opto-acoustic breast imaging solutions, including the Imagio Breast Imaging System, which uses non-invasive laser light and sound to display real-time functional and anatomic images to help radiologists differentiate malignant tissue, and SenoGram AI Decision Support, an integrated AI tool to classify likelihood of malignancy with greater precision and accuracy.
Products and services
- Imagio Breast Imaging System: Constructs opto-acoustic images using non-invasive laser light and sound, displaying real-time functional and anatomic breast features to help radiologists differentiate malignant tissue
- SenoGram AI Decision Support: AI-based decision support integrated with the Imagio system that helps radiologists classify the likelihood of malignancy with greater precision and accuracy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Seno Medical
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
Immunicum
HQ: Sweden
Website
- Description: Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicum company profile →
Hybrigenics
HQ: France
Website
- Description: Provider of bioinformatics platforms to identify, validate, and inhibit protein interactions to develop cancer therapeutics; a biopharmaceutical company focused on R&D of new targets and therapies against cancer, researching deubiquitinating enzymes (DUBs), and having stopped development of inecalcitol, a vitamin D receptor agonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrigenics company profile →
Precirix
HQ: Belgium
Website
- Description: Provider of radio-immunotherapeutic drugs for cancer patients, developing single-domain antibody CAM-H2 targeting HER2 combined with iodine-131 in Phase I/II for HER2-positive metastatic breast, gastric, and gastroesophageal cancers; FAP-targeting radiopharmaceutical program entering clinical trials; and a theranostic approach using imaging to select patients before treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precirix company profile →
Aadi Bioscience
HQ: United States
Website
- Description: Provider of a potential mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aadi Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Seno Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Seno Medical
2.2 - Growth funds investing in similar companies to Seno Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Seno Medical
4.2 - Public trading comparable groups for Seno Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →